Skip to content

The effect of L-Arginine supplement on sexual function in diabetic postmenopausal women

The effect of L-Arginine supplement on sexual function in diabetic postmenopausal women: a double blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150630022991N17
Enrollment
62
Registered
2025-06-10
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual dysfunction. Sexual dysfunction not due to a substance or known physiological condition

Interventions

Intervention 1: Intervention group: They receive 2 grams of L-arginine orally in capsule form daily. Intervention 2: Control group: They receive 2 grams of starch orally in capsule form daily.

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 70 Years

Inclusion criteria

Inclusion criteria: All women who are postmenopausal (up to 70 years old) and have a spouse have diabetes, for at least one year before the start of the intervention do not have an active intestinal ulcer.

Exclusion criteria

Exclusion criteria: Having major depressive disorder Patients who recently had a heart attack Unstable marital relationships such that there is no sexual intercourse between the couple Having asthma and allergies Having herpes Taking medications such as nitroglycerin and drugs to treat impotence (Viagra) Kidney and liver failure People who did not take their medication properly during the study period.

Design outcomes

Primary

MeasureTime frame
Sexual performance index. Timepoint: Before intervention, weeks 4 and 8 after the start of the study. Method of measurement: It is measured using the "Female Sexual Function Index" questionnaire.

Secondary

MeasureTime frame
Sexual distress. Timepoint: Before intervention, weeks 4 and 8 after the start of the study. Method of measurement: It is measured with the "Female Sexual Distress Scale- Revised" questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSussan Moudi

Babol University of Medical Sciences

sussan.mouodi@mubabol.ac.ir+98 11 3236 5683

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026